Marc A. Shapiro

1.3k total citations
17 papers, 725 citations indexed

About

Marc A. Shapiro is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Marc A. Shapiro has authored 17 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in Marc A. Shapiro's work include Lung Cancer Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Marc A. Shapiro is often cited by papers focused on Lung Cancer Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Marc A. Shapiro collaborates with scholars based in United States. Marc A. Shapiro's co-authors include Alok A. Khorana, Anirban Maitra, Supriya G. Mohile, Pamela B. Mangu, Jordan Berlin, Theodore S. Hong, Anitra Engebretson, Matthew P. Mumber, Herbert J. Zeh and Susan G. Urba and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer and Metastasis Reviews.

In The Last Decade

Marc A. Shapiro

17 papers receiving 716 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc A. Shapiro United States 8 560 381 182 160 143 17 725
Elisa Sperti Italy 15 634 1.1× 232 0.6× 125 0.7× 263 1.6× 134 0.9× 28 783
Renjian Jiang United States 16 406 0.7× 220 0.6× 151 0.8× 209 1.3× 107 0.7× 61 689
Assaf Moore Israel 15 339 0.6× 277 0.7× 122 0.7× 148 0.9× 84 0.6× 52 653
Anitra Engebretson United States 6 847 1.5× 317 0.8× 291 1.6× 245 1.5× 240 1.7× 9 957
Lorraine C. Drapek United States 11 499 0.9× 273 0.7× 150 0.8× 302 1.9× 143 1.0× 42 659
Sabrina Hundt Germany 8 644 1.1× 365 1.0× 94 0.5× 190 1.2× 69 0.5× 9 790
Henriette Golcher Germany 12 602 1.1× 312 0.8× 260 1.4× 357 2.2× 183 1.3× 25 879
Stephanie T. Chang United States 13 426 0.8× 183 0.5× 100 0.5× 261 1.6× 129 0.9× 23 742
Aoi Hayasaki Japan 12 719 1.3× 375 1.0× 209 1.1× 417 2.6× 219 1.5× 75 862
Cassadie Moravek United States 7 590 1.1× 175 0.5× 291 1.6× 140 0.9× 119 0.8× 14 674

Countries citing papers authored by Marc A. Shapiro

Since Specialization
Citations

This map shows the geographic impact of Marc A. Shapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc A. Shapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc A. Shapiro more than expected).

Fields of papers citing papers by Marc A. Shapiro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc A. Shapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc A. Shapiro. The network helps show where Marc A. Shapiro may publish in the future.

Co-authorship network of co-authors of Marc A. Shapiro

This figure shows the co-authorship network connecting the top 25 collaborators of Marc A. Shapiro. A scholar is included among the top collaborators of Marc A. Shapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc A. Shapiro. Marc A. Shapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lee, Monica, Meera Patel, Hadil Zureigat, et al.. (2024). Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.. Journal of Clinical Oncology. 42(16_suppl). 8096–8096. 1 indexed citations
2.
Lemmon, Christopher A., Gregory M.M. Videtic, Sudish C. Murthy, et al.. (2022). A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC. JTO Clinical and Research Reports. 3(7). 100359–100359. 7 indexed citations
3.
Lemmon, Christopher A., Gregory M.M. Videtic, Sudish C. Murthy, et al.. (2020). A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). 9009–9009. 10 indexed citations
4.
Patil, Pradnya D., Marc A. Shapiro, Nooshin Hashemi Sadraei, & Nathan A. Pennell. (2019). An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. 24(4). 457–e126. 2 indexed citations
5.
Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(2). 97–104. 137 indexed citations
6.
Khorana, Alok A., Pamela B. Mangu, Jordan Berlin, et al.. (2017). Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 35(20). 2324–2328. 143 indexed citations
7.
Khorana, Alok A., Pamela B. Mangu, Jordan Berlin, et al.. (2016). Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 34(21). 2541–2556. 266 indexed citations
8.
Parekh, Hiral D., Katherine Tullio, Paul Elson, et al.. (2016). The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). e21688–e21688. 2 indexed citations
9.
Shapiro, Marc A., et al.. (2016). Patient-centered outcomes with post-approval nivolumab in metastatic NSCLC at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology. 34(7_suppl). 29–29. 1 indexed citations
10.
11.
Rakshit, Sagar, Mahdi Orooji, Niha Beig, et al.. (2016). Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). 11582–11582. 4 indexed citations
12.
Shapiro, Marc A., James Stevenson, Nathan A. Pennell, et al.. (2015). Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology. 33(15_suppl). 6609–6609. 1 indexed citations
13.
Sohal, Davendra, Shiva Shrotriya, Robert Pelley, et al.. (2015). Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Cancer. 121(11). 1779–1784. 26 indexed citations
14.
Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2014). SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. Journal of Clinical Oncology. 32(15_suppl). 7514–7514. 40 indexed citations
15.
Shapiro, Marc A.. (2012). The role of adjuvant chemotherapy in early-stage and locally advanced non–small cell lung cancer. Cleveland Clinic Journal of Medicine. 79(5 e-suppl 1). S42–S45. 7 indexed citations
16.
Videtic, Gregory M.M., Kevin L. Stephans, N.M. Woody, et al.. (2012). Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. Practical Radiation Oncology. 3(4). 301–306. 23 indexed citations
17.
Reddy, Sreekanth, et al.. (2003). Prostate cancer in black and white Americans. Cancer and Metastasis Reviews. 22(1). 83–86. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisa Sperti Breakdown of academic impact, for papers by Renjian Jiang Breakdown of academic impact, for papers by Assaf Moore Breakdown of academic impact, for papers by Anitra Engebretson Breakdown of academic impact, for papers by Lorraine C. Drapek Breakdown of academic impact, for papers by Sabrina Hundt Breakdown of academic impact, for papers by Henriette Golcher Breakdown of academic impact, for papers by Stephanie T. Chang Breakdown of academic impact, for papers by Aoi Hayasaki Breakdown of academic impact, for papers by Cassadie Moravek
Rankless by CCL
2026